# multiomics-survival-modeling

Multi-omics survival modeling in breast cancer integrating gene expression and copy number alterations (CNAs) to identify paclitaxel resistance‚Äìinformed prognostic genes, pathways, and a validated gene signature. The repository includes Cox proportional hazards modeling, Kaplan‚ÄìMeier analysis, RMST, time-dependent AUC, pathway scoring, network analysis, and cross-cohort validation using METABRIC and TCGA-BRCA datasets.

---

# Paclitaxel Resistance‚ÄìInformed Multi-Omics Survival Modeling in Breast Cancer

This repository contains the full analysis pipeline accompanying the manuscript:

**‚ÄúMulti-omics survival modeling identifies paclitaxel resistance‚Äìinformed prognostic genes and pathways and derives a validated gene signature in breast cancer.‚Äù**

The code implements a resistance-informed survival modeling framework that integrates gene expression, copy number alterations (CNAs), and clinical covariates to identify robust prognostic genes, pathways, and a parsimonious gene-level prognostic signature validated across independent cohorts.

---

## Overview

Most prognostic biomarkers in breast cancer are identified independently of treatment-related biology. In this study, survival analyses are explicitly anchored to **paclitaxel resistance‚Äìassociated genes and pathways**, previously identified using deep learning‚Äìbased drug response modeling and pathfindR enrichment analysis.

Using two independent breast cancer cohorts (**METABRIC** and **TCGA-BRCA**), this repository implements:

- Gene-level and pathway-level Cox proportional hazards (CoxPH) modeling  
- Integration of gene expression and copy number alteration (CNA) data  
- Clinical covariate adjustment (age, tumor stage, PAM50 subtype)  
- Cross-cohort validation with fixed, training-derived cutoffs  
- Kaplan‚ÄìMeier (KM) analysis, log-rank testing, RMST, and time-dependent AUC analyses  
- Network-based contextualization and hypergeometric over-representation testing  

All analyses and figures reported in the manuscript are fully reproducible using the code provided here.

---

## Data Sources

This project uses publicly available datasets:

### METABRIC
- Gene expression data (Illumina microarrays, z-scores)
- Copy number alteration (CNA) data (GISTIC scores)
- Clinical survival data  
- Source: Synapse (`syn1688369`)

### TCGA-BRCA
- RNA-seq gene expression data (RSEM ‚Üí TPM ‚Üí log2 transformation ‚Üí z-score normalization)
- CNA profiles (Affymetrix SNP 6.0 arrays; CBS segmentation)
- Clinical data retrieved using the `TCGAbiolinks` R package

All analyses use **overall survival (OS)** as the clinical endpoint.

‚ö†Ô∏è Raw data are not redistributed in this repository. Scripts assume the user has appropriate access to the original datasets.

---

## Analysis Workflow

### Data Preprocessing
- Expression normalization and z-score standardization
- CNA binarization (altered vs. copy-neutral)
- Clinical covariate harmonization (tumor stage and PAM50 subtype)

### Gene-Level Survival Modeling
- CoxPH models using:
  - Expression only
  - CNA only
  - Expression + CNA
  - Expression √ó CNA interaction
- Models evaluated with and without clinical covariates
- Cross-cohort meta-analysis of hazard ratios

### Pathway-Level Survival Modeling
- Pathway activity scores derived from paclitaxel resistance‚Äìassociated pathways
- Separate expression-based and CNA-based pathway scores
- Identification of independently prognostic pathways

### Prognostic Signature Construction
- Selection of non-redundant prognostic genes
- Multicollinearity assessment using:
  - Point-biserial correlation
  - Phi coefficient
- Model selection based on:
  - Concordance index (C-index)
  - Akaike information criterion (AIC)
  - Likelihood ratio tests (LRT)
- Final gene signature trained in METABRIC and validated in TCGA-BRCA

### Survival Stratification and Temporal Evaluation
- Kaplan‚ÄìMeier analyses with fixed cutoffs
- Restricted Mean Survival Time (RMST) analysis
- Time-dependent AUC analyses up to 200 months

### Network Analysis
- Integration of prognostic genes and pathways
- Visualization of gene‚Äìpathway relationships
- Hypergeometric testing for non-random accumulation of prognostic genes

---

## Key Findings Implemented in This Repository
- Identification of **SERPINE1** (expression) and **CLDN1, CXCR4, LAMB2, and LYPD6B** (CNAs) as reproducible prognostic genes across independent cohorts
- Construction of a parsimonious gene-level prognostic signature with robust cross-cohort validation
- Identification of **Ras signaling** as the only pathway retaining independent prognostic significance after clinical adjustment
- Demonstration of a non-random accumulation of prognostic genes within the **Axon guidance** pathway
- Evidence that gene-level prognostic signatures outperform pathway-level CNA scores in survival modeling

---

## Software & Dependencies

### Software and Package Versions
All analyses were performed in **R (version ‚â• 4.4.2)**.

#### Core R Packages
- **survival** (v3.8.3): CoxPH modeling, C-index, AIC, LRT
- **survminer** (v0.5.1): Kaplan‚ÄìMeier visualization and log-rank testing
- **survRM2** (v1.0.4): Restricted mean survival time (RMST)
- **timeROC** (v0.4): Time-dependent AUC
- **TCGAbiolinks** (v2.34.1): TCGA data retrieval
- **dplyr** (v1.1.4), **tidyr** (v1.3.1): Data manipulation
- **ggplot2** (v4.0.1): Figure generation
- **igraph** (v2.2.1): Network analysis
- **stats** (base R): Statistical testing and meta-analysis

**Notes**
- Meta-analyses use inverse-variance weighting on log hazard ratios.
- All figures are generated using `ggplot2`.
- Exact methodological details are reported in the manuscript.

---

## Reproducibility
- **METABRIC** is used as the training cohort.
- **TCGA-BRCA** serves as an independent validation cohort.

### Cutoff Strategy
- **Gene-level analyses**
  - Expression-based stratification uses **cohort-specific maxstat cutoffs**.
  - CNA-based stratification uses **cohort-specific median cutoffs**.

- **Pathway-level and gene-signature analyses**
  - All cutoffs are derived **exclusively from METABRIC**.
  - The same predefined cutoffs are applied **unchanged** to TCGA-BRCA.

No cohort-specific tuning, re-optimization, or threshold adjustment is performed for pathway-level or signature-level validation.

---

## Contact

**Corresponding author**  
Osman Ugur Sezerman  
üìß ugur.sezerman@acibadem.edu.tr
